On January 23, 2024, Heron Therapeutics announced the FDA had approved its sNDA for bupivacaine and meloxicam extended-release solution to expand the indication to include soft tissue and orthopedic surgical procedures, including procedures in which direct exposure to articular cartilage is avoided.

Related Keywords

Alexander Sah , Crosslink Life Sciences , Heron Therapeutics Inc , Drug Administration , Sah Orthopaedic Associates , Sah Orthopaedic , Heron Therapeutics , New Drug Application , Vial Access Needle , Craig Collard ,